Cytokinetics, Inc.
Cytokinetics Announces Positive FOREST-HCM Data at ACC Scientific Session
Summary
On April 5, 2024, Cytokinetics, Incorporated announced additional 48-week data from FOREST-HCM, an open-label extension clinical study of aficamten in patients with hypertrophic cardiomyopathy (HCM), at the 73rd Annual American College of Cardiology (ACC) Scientific Session. The updated data set focused on 46 patients who had completed 48 weeks of follow-up. Treatment with aficamten resulted in substantial reductions in left ventricle outflow tract gradient (LVOT-G) and improvements in symptoms and cardiac biomarkers. Notably, 75% of patients were receiving the 15 mg or 20 mg dose of aficamten, with statistically significant improvements observed in NYHA Functional Class and NT-proBNP levels. There were also significant improvements in cardiac structure and function, including decreases in maximum wall thickness and left atrial volume index. The treatment was well-tolerated with no treatment-related serious adverse events. However, there was a modest reduction in left ventricular ejection fraction (LVEF) from baseline to Week 48.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement